Eduardo is a Brazilian neuroscientist, with a degree in biomedicine, a masters in psychopharmacology and a doctorate in neurosciences. He led studies on the effects of Ayahuasca using EEG and participated in the first neuroimaging study of the brain on LSD as honorary researcher at Imperial College London. In 2018 he published an article in Frontiers in Pharmacology about the Psychedelic Paradigm, which currently has over 90,000 views, sitting at the top 1% most downloaded and 6% most cited articles of the entire Frontiers journal series. Between 2015 and 2019, Eduardo carried out Brazil’s first clinical trial of MDMA to address PTSD, whose encouraging results were published by the Brazilian Journal of Psychiatry. In 2011 he founded Phaneros Institute, which in February of 2022 launched the first facilitators' training in MDMA and psilocybin-assisted psychotherapy in Latin America. Eduardo is Scientific Advisor to both Ocama Partners and the Global Initiative for Psychedelic Science Economics (GIPSE).